CHU Sainte-Justine Université de Montréal

About our team members

test

 

Following the thalidomide disaster of the 1960s, there is an increased awareness in the general population of the potential adverse effects of the use of medication in pregnancy. Furthermore, as the age of childbearing continues to rise, the prevalence of pregnant women with chronic diseases such as hypertension, diabetes or high cholesterol increases as well. Considering that almost 50% of pregnancies are unplanned, women who become pregnant at older ages are possibly already on pharmacological therapies in their first trimester. To exercise caution, many women then find themselves faced with a difficult dilemma: continue or discontinue their medications. The choice almost always involves risks and benefits to themselves and to the unborn child.

The mission of our research team is to determine the risks and benefits associated with the use of drugs during pregnancy and lactation, to inform evidence-based decision-making by health professionals and pregnant women.

Our team consists of members from various disciplines such as pharmacy, medicine, biology, biostatistics, epidemiology and pharmacoeconomics, working in the laboratory of Dr. Anick Bérard at the Centre Hospitalier Universitaire (CHU) Sainte-Justine Research Center, affiliated with the University of Montreal.

Also affiliated with the Faculty of Pharmacy of the University of Montreal, we are part of the research theme "Medication and Population Health" which focuses on the use of drugs, determinants of use, and risks and benefits, including the evaluation of interventions to optimize their use.

Mental health in pregnant women